22-Apr-2021

Biotech Dispatch: Kazia licenses global rights to potential first-in-class oncology drug

Kazia Therapeutics (ASX:KZA) has entered into a worldwide exclusive licensing agreement and a master services agreement with European company Evotec SE for EVT801, a small molecule, first-in-class oncology drug candidate.

21-Apr-2021

Ausbiz: Three big moves in seven weeks; how Kazia is turbocharging biotech innovation

Three big moves in seven weeks; how Kazia is turbocharging biotech innovation

Kazia Therapeutics CEO James Garner is a very happy man. After securing the company's third key licence in seven weeks, he tells us about the why's and how's.

21-Apr-2021

Stockhead: Kazia Therapeutics completes third licensing deal in seven weeks

Kazia Therapeutic‘s chief executive says he could do with catching up on sleep after a “whirlwind” seven weeks in which the $185 million cancer-focused Sydney biotech completed three different cross-border licensing deals.

Kazia on Monday announced it had licensed global rights to a promising small molecule oncology drug candidate from Germany-based Evotec SE (FRA:EVT) for an upfront payment of €1 million ($1.6 million), plus contingent milestone payments of up to €308 million ($480 million).